IL23A and autoimmune disease: We previously constructed and expressed a IL-23 soluble receptor molecule described as human interleukin 23-receptor cytokine receptor-binding homology region (hIL-23R-CHR) [18], which can directly antagonize IL-23, significantly improve the symptoms of various autoimmune diseases in model mice, and decrease the incidence through the IL-23/IL-17 pathway [19,20].